Vistagen Therapeutics, Inc. VTGN 深 滬
已收盤 08-07 16:00:00 美东时间
0.2876
+0.004
+1.34%
華盛通- 最 高0.31
- 今 開0.2872
- 成交量 255.59万股
- 最 低 0.282
- 昨 收 0.2838
- 總市值 1276.28万
- 52周最高 5.14
- 市盈率 靜 --
- 換手率 5.76%
- 52周最低 0.198
- 委 比 0.00%
- 總股本 4437.69万
- 歷史最高 495.00
- 量 比 0.10
- 振 幅 9.87%
- 歷史最低 0.198
- 每 手 1
- 風險率 1.59%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多VistaGen reports Phase 2 fasedienol trial topline results
VistaGen Therapeutics ( ($VTGN) ) has shared an announcement. On August 6, 2026...
08-07 05:36
Stifel Nicolaus Remains a Hold on VistaGen Therapeutics (VTGN)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Hold...
07-06 13:55
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
Vistagen Inc. (NASDAQ:VTGN) on Monday reported that its Phase 3 PALISADE-4 trial of intranasal fasedienol for the acute treatment of social anxiety disorder did not meet its primary endpoint in the overall study population. However, the company identified a statistically significant benefit in a pos...
07-01 01:35
VistaGen Therapeutics Q4 EPS $(0.37) Misses $(0.30) Estimate, Sales $465.000K Beat $320.000K Estimate
VistaGen Therapeutics (NASDAQ:VTGN) reported quarterly losses of $(0.37) per share which missed the analyst consensus estimate of $(0.30) by 23.33 percent. This is a 15.91 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $465.0...
06-16 05:18
VistaGen Completes Phase 3 PALISADE-4 Trial Milestone
VistaGen Therapeutics ( ($VTGN) ) just unveiled an update. On May 8, 2026, Vist...
05-09 06:07
Vistagen Completes Last Patient Visit in PALISADE-4 Phase 3 Public Speaking Challenge Study of Fasedienol for Acute Treatment of Social Anxiety Disorder, With Topline Results Expected In Q2
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,
05-08 19:42
VistaGen Advances Refisolone Nasal Spray in U.S. Phase 2
VistaGen Therapeutics ( ($VTGN) ) has shared an announcement. On April 22, 2026...
04-29 04:31
Vistagen Receives "Study May Proceed" Letter From FDA Under IND Application For Refisolone Nasal Spray For Treatment Of Vasomotor Symptoms Due To Menopause
Vistagen (NASDAQ:VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience with nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines,
04-22 20:35
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers BNB Plus (NASDAQ:BNBX) stock moved upwards by 12.7% to $0.65 during Tu...
04-15 05:05
